XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1

CSL Behring collaboration	3 Months Ended
	Mar. 31, 2024
CSL Behring collaboration
CSL Behring collaboration	3 CSL Behring collaboration ​ On June 24, 2020, uniQure biopharma B.V. entered into a commercialization and license agreement with CSL Behring (the “CSL Behring Agreement”), pursuant to which CSL Behring received exclusive global rights to HEMGENIX®. ​ The transaction became fully effective on May 6, 2021. ​ License revenue The Company recognized $1.2 million of royalty revenue in the three months ended March 31, 2024, compared to nil in the three months ended March 31, 2023. Royalties on the sale of HEMGENIX® are recorded once earned and are presented as license revenue. Accounts receivable and contract asset ​ As of December 31, 2023, the Company recorded accounts receivable of $4.0 million from CSL Behring related to collaboration services, contract manufacturing revenue and royalty revenue. ​ As of March 31, 2024, the Company had accounts receivable of $10.6 million from CSL Behring related to collaboration services, contract manufacturing revenue and royalty revenue. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

X

- References

No definition available.

+ Details

Name:	qure_CollaborativeArrangementAbstract
Namespace Prefix:	qure_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-SubTopic 10
-Topic 808
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-SubTopic 10
-Topic 808
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 808
-Publisher FASB
-URI https://asc.fasb.org//808/tableOfContent

+ Details

Name:	us-gaap_CollaborativeArrangementDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration